生物活性 | Cl-amidine hydrochloride is an orally activepeptidylarginine deminase (PAD)inhibitor, withIC50values of 0.8 μM, 6.2 μM and 5.9 μM for PAD1, PAD3, and PAD4, respectively. Cl-amidine hydrochloride inducesapoptosisincancercells. Cl-amidine hydrochloride inducesmicroRNA(miR)-16 (miRNA-16, microRNA-16) expression and causes cell cycle arrest. Cl-Amidine hydrochloride prevents histone 3 citrullination and neutrophil extracellular trap formation, and improves survival in a murine sepsis model[1][2][3][4][5]. |
IC50& Target | IC50: 0.8 μM (PAD1), 5.9 μM (PAD4), 6.2 μM (PAD3)[1][5]. |
体外研究 (In Vitro) | Cl-amidine is a bioavailable haloacetamidine-based compound that inhibits all the active PAD isozymes with near equal potency (kinact/KI=13,000 M-1omin-1 for PAD4)[1]. Cl-amidine (0, 5, 10, 15, 20, 25, 50 μg/mL, 24 hours) induces apoptosis in TK6 lymphoblastoid cells and HT29 colon cancer cells in a dose-dependent manner. Interestingly, the colon cancer cell line (HT29) is relatively resistant to apoptosis caused by Cl-amidine[2]. Cl-Amidine prevents histone 3 citrullination and neutrophil extracellular trap formation, and improves survival in a murine sepsis model[4].
Apoptosis Analysis[2]. Cell Line: | TK6 lymphoblastoid cells and HT29 colon cancer cells. | Concentration: | 0, 5, 10, 15, 20, 25, 50 μg/mL. | Incubation Time: | 24 h. | Result: | Induced apoptosis dose-dependently. |
|
体内研究 (In Vivo) | Cl-amidine (75 mg/kg, ip once daily) suppresses and treats DSS-induced colitis in mice[2]. Cl-amidine (5, 25, 75 mg/kg, oral gavage, once daily) leads to significant reductions in the histology scores dose-dependently[2].
Animal Model: | C57BL/6 mice (8-12 wk old, DSS mouse model of colitis)[2]. | Dosage: | 75 mg/kg. | Administration: | IP once daily. | Result: | Suppressed PAD activity, protein citrullination, and PAD levels in the colon in vivo. |
Animal Model: | C57BL/6 mice (8-12 wk old, DSS mouse model of colitis)[2]. | Dosage: | 5, 25, 75 mg/kg. | Administration: | Oral gavage once daily. | Result: | Led to significant reductions in the histology scores. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | -20°C, stored under nitrogen, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture) |
溶解性数据 | In Vitro: DMSO : 50 mg/mL(143.99 mM;Need ultrasonic) H2O : 50 mg/mL(143.99 mM;Need ultrasonic) 配制储备液 1 mM | 2.8799 mL | 14.3993 mL | 28.7985 mL | 5 mM | 0.5760 mL | 2.8799 mL | 5.7597 mL | 10 mM | 0.2880 mL | 1.4399 mL | 2.8799 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (stored under nitrogen, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: PBS Solubility: 5.5 mg/mL (15.84 mM); Clear solution; Need ultrasonic 2. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 1.25 mg/mL (3.60 mM); Clear solution
此方案可获得 ≥ 1.25 mg/mL (3.60 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 3. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 1.25 mg/mL (3.60 mM); Clear solution
此方案可获得 ≥ 1.25 mg/mL (3.60 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 4. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 1.25 mg/mL (3.60 mM); Clear solution
此方案可获得 ≥ 1.25 mg/mL (3.60 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|